We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bio-Rad and Myriad RBM Partner to Develop Immunoassay Kits
News

Bio-Rad and Myriad RBM Partner to Develop Immunoassay Kits

Bio-Rad and Myriad RBM Partner to Develop Immunoassay Kits
News

Bio-Rad and Myriad RBM Partner to Develop Immunoassay Kits

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bio-Rad and Myriad RBM Partner to Develop Immunoassay Kits"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bio-Rad Laboratories, Inc. and Myriad RBM, Inc. have announced that they have partnered to develop and distribute high-quality immunoassay kits.

Under the terms of the agreement, Myriad RBM grants Bio-Rad exclusive distribution rights, for research purposes, to the largest catalog of quantitative multiplexed immunoassays currently available to run on the Bio-Plex® 200, Bio-Plex® 3D, and Bio-Plex® MAGPIX™ instruments.

Myriad RBM's assays address researchers' needs for multiplex testing of samples with very low volumes when studying toxicology, oncology, immunology, and cardiovascular and other diseases. The new assays expand Bio-Rad's current suite of assays.

"Together we are able to provide hundreds of new biomarkers for both human and non-human panels to our Bio-Plex multiplex immunoassay system menu," said Brad Crutchfield, Bio-Rad Vice President and Group Manager, Life Science Group.

Crutchfield continued, "Moving forward, Myriad RBM and Bio-Rad will collaborate to design new products to meet the evolving requirements of our customers."

"This agreement combines Myriad RBM's industry-leading menu of multiplexed immunoassays with Bio-Rad's unrivaled global commercial distribution capabilities," said Craig Benson, President of Myriad RBM.

Benson continued, "Our partnership with Bio-Rad will help researchers and clinicians on the front lines of medicine to develop biomarker profiles that may predict, detect, or monitor disease progression in an effort to optimize treatment and improve patient care."

Advertisement